Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report)'s stock price traded up 5.6% during trading on Monday . The company traded as high as $1.14 and last traded at $1.13. 308,303 shares traded hands during mid-day trading, a decline of 33% from the average session volume of 458,218 shares. The stock had previously closed at $1.07.
Tiziana Life Sciences Stock Up 5.6 %
The company has a fifty day moving average of $1.09 and a two-hundred day moving average of $0.94.
Institutional Investors Weigh In On Tiziana Life Sciences
Institutional investors and hedge funds have recently made changes to their positions in the company. Sanctuary Advisors LLC acquired a new stake in shares of Tiziana Life Sciences during the third quarter worth $864,000. Geode Capital Management LLC boosted its stake in Tiziana Life Sciences by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock valued at $171,000 after acquiring an additional 27,041 shares during the period. Zhang Financial LLC grew its holdings in shares of Tiziana Life Sciences by 34.3% during the fourth quarter. Zhang Financial LLC now owns 93,187 shares of the company's stock valued at $65,000 after purchasing an additional 23,800 shares during the last quarter. Finally, Bison Wealth LLC acquired a new stake in shares of Tiziana Life Sciences during the 4th quarter worth approximately $30,000.
About Tiziana Life Sciences
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
